SYRE - Spyre Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.66
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.00
DETAILS
HIGH:
$53.00
LOW:
$43.00
MEDIAN:
$48.00
CONSENSUS:
$48.00
UPSIDE:
10.47%
Market Cap:
2.62B
Volume:
604,850
Avg Volume:
748,485
52 Week Range:
10.91-44.81
Sector:
Healthcare
Industry:
Biotechnology
Beta:
3.16
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
73
IPO Date:
2016-04-07
EPS (TTM):
-1.98
P/E Ratio:
-73.04
Revenue (TTM):
N/A
Total Assets:
777.78M
Total Debt:
N/A
Cash & Equiv:
85.72M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $-0.15 | $-0.68 | +77.9% | — | — | — |
| 2025-08-05 | $-0.49 | $-0.73 | +32.9% | — | — | — |
| 2025-05-08 | $-0.74 | $-0.76 | +2.6% | — | — | — |
| 2025-02-27 | $-0.81 | $-0.89 | +9.0% | — | $4.0M | — |
| 2024-11-07 | $-1.36 | $-0.80 | -70.0% | — | $2.6M | — |
| 2024-08-07 | $-0.86 | $-0.90 | +4.4% | — | $4.0M | — |
| 2024-05-09 | $-1.20 | $-0.90 | -33.3% | — | — | — |
| 2024-02-29 | $-2.28 | $-0.48 | -375.0% | $1.0M | $220000 | +373.6% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 886,000 | 2.33M | 18.74M | 0 | 0 | 3.89M | 5.21M | 4.63M | 6.08M | 0 |
| Net Income | (155.20M) | (208.02M) | (338.79M) | (83.81M) | (65.80M) | (80.89M) | (78.25M) | (44.35M) | (27.24M) | (21.70M) | (11.29M) | (10.35M) |
| EPS | -1.98 | -3.18 | -46.15 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -24.71 | -18.91 |
| Total Assets | 777.78M | 608.48M | 341.86M | 71.14M | 109.93M | 161.62M | 83.18M | 77.74M | 56.08M | 67.06M | 38.65M | 2.93M |
| Total Debt | 0 | 0 | 0 | 4.63M | 5.06M | 5.45M | 5.06M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 85.72M | 89.42M | 188.89M | 34.86M | 15.14M | 90.09M | 19.25M | 22.46M | 12.82M | 47.75M | 29.29M | 2.62M |
| Operating Cash Flow | (169.25M) | (157.41M) | (99.91M) | (80.14M) | (53.72M) | (75.78M) | (65.69M) | (32.19M) | (24.61M) | (18.84M) | (10.98M) | (7.33M) |
| Free Cash Flow | (169.25M) | (157.41M) | (99.91M) | (80.18M) | (54.29M) | (80.06M) | (67.18M) | (32.62M) | (25.23M) | (19.05M) | (11.19M) | (7.52M) |
| FCF per Share | -0.49 | -3.35 | -14.49 | -23.78 | -20.64 | -37.50 | -52.57 | -39.16 | -41.70 | -48.64 | -24.48 | -13.74 |
| Book Value | 715.24M | 517.80M | 184.02M | 50.30M | 83.94M | 139.83M | 60.08M | 67.43M | 50.34M | 62.97M | 36.10M | 1.87M |
| Cash & ST Investments | 756.53M | 603.09M | 339.28M | 55.71M | 93.13M | 146.27M | 71.95M | 74.51M | 50.30M | 63.50M | 33.06M | 2.62M |
| ROC Equity | -0.22 | -0.40 | -1.84 | -1.67 | -0.78 | -0.58 | -1.30 | -0.66 | -0.54 | -0.34 | -0.31 | -5.53 |